Back
Revance Therapeutics 10K Form
Sell
10
RVNC
Revance Therapeutics
Last Price:
3.84
Seasonality Move:
2.15%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RVNC News And Ratings
See the #1 stock for the next 7 days that we like better than RVNC
RVNC Financial Statistics
Sales & Book Value
| Annual Sales: | $234.04M |
|---|---|
| Cash Flow: | $-41.15M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-1.55 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -1.94000 |
|---|---|
| Net Income (TTM): | $-184.44M |
| Gross Margin: | $159.68M |
| Return on Equity: | 0% |
| Return on Assets: | -37.25% |
Revance Therapeutics Earnings Forecast
Key Revance Therapeutics Financial Ratios
- The Gross Profit Margin over the past 13 years for RVNC is 68.23%.
- The Selling, General & Administrative Expenses for RVNC have been equal to 124.87% of Gross Profit Margin.
- The Research & Development expenses have been 33.93% of Revenue.
- The Interest Expense is -5.97% of Operating Income.
- The Net Earning history of RVNC is -138.43% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 6 years.
Revance Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | RVNC |
| CUSIP: | 761330 |
| Website: | revance.com |
Debt
| Debt-to-Equity Ratio: | -2.64 |
|---|---|
| Current Ratio: | 4.12 |
| Quick Ratio: | 2.9 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RVNC Technical Analysis vs Fundamental Analysis
Sell
10
Revance Therapeutics (RVNC)
is a Sell
Is Revance Therapeutics a Buy or a Sell?
-
Revance Therapeutics stock is rated a Sell
The current Revance Therapeutics [RVNC] share price is $3.80. The Score for RVNC is 10, which is 80% below its historic median score of 50, and infers higher risk than normal.